Brokerages maintain cautious stance on Dr. Lal PathLabs post

The diagnostics player reported a 52.4 percent year-on-year rise in consolidated net profit at Rs 109.3 crore for the July-September quarter of the current financial year

Related Keywords

India , Lal Pathlabs , Lal Pathlab , , Kotak Institutional Equities , Managing Director , Net Profit , South India , Dr Lal Pathlabs , Iagnostics , Brokerage View , Q2 Earnings , Stock Price , Uzzing Stocks ,